Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.
Mayne KJ. et al, (2025), Nephrol Dial Transplant, 40, 720 - 730
Key priorities for the implementation of the 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes in low-resource settings.
Marx N. et al, (2025), Eur Heart J Qual Care Clin Outcomes
Type 2 diabetes and cause-specific mortality in Mexico City: a Mendelian randomisation analysis
EMBERSON J. et al, (2025), The Lancet Regional Health - Americas
Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2024 Clinical Practice Guideline.
Madero M. et al, (2025), Ann Intern Med
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
EMPA-KIDNEY Collaborative Group None. et al, (2025), N Engl J Med, 392, 777 - 787
The prevention and management of chronic kidney disease among patients with metabolic syndrome.
Zhu D. et al, (2025), Kidney Int
Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease.
Zhu D. et al, (2025), Nephrol Dial Transplant, 40, i70 - i79
Heart failure events in randomized controlled trials for adults receiving maintenance dialysis: a meta-epidemiologic study.
Collister D. et al, (2025), Nephrol Dial Transplant, 40, 371 - 384
Abstract 4113475: Association of Age at Diabetes Diagnosis and All-cause and Cardiovascular Mortality among 600,000 US Adults
Thomson B. et al, (2024), Circulation, 150, a4113475 - a4113475
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.
Judge PK. et al, (2024), Nephrol Dial Transplant
Alcohol and mortality in Mexico: prospective study of 150 000 adults.
Trichia E. et al, (2024), Lancet Public Health, 9, e907 - e915
In adults with BMI ≥27 kg/m2 and CVD, but without diabetes, semaglutide reduced MACE, regardless of baseline HbA1c level.
Zhu D. and Herrington WG., (2024), Ann Intern Med, 177
In HF, T2D, CKD, or atherosclerotic CVD, SGLT2 inhibitors reduce HF hospitalizations and CV mortality.
Zhu D. and Herrington WG., (2024), Ann Intern Med, 177
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD: A Meta-Analysis of CKD Progression Trials.
Fletcher RA. et al, (2024), Clin J Am Soc Nephrol, 19, 1180 - 1182
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.
Apperloo EM. et al, (2024), Lancet Diabetes Endocrinol, 12, 545 - 557
Diabetic Kidney Disease - Semaglutide Flows into the Mainstream.
Herrington WG. and Haynes R., (2024), N Engl J Med, 391, 178 - 179
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial.
Mayne KJ. et al, (2024), Clin J Am Soc Nephrol, 19, 1119 - 1129
Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
Patel SM. et al, (2024), Circulation, 149, 1789 - 1801
Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEY.
Nangaku M. et al, (2024), Clin Exp Nephrol, 28, 588 - 595